ArjoHuntleigh: Major study demonstrates significant reduction in mortality using prone positioning on patients presenting with

  ArjoHuntleigh: Major study demonstrates significant reduction in mortality
  using prone positioning on patients presenting with severe Acute Respiratory
  Distress Syndrome (ARDS)

Business Wire

MALMÖ, Sweden -- July 12, 2013

A recent study in the New England Journal of Medicine (2013;368:2159-2168)
concluded that prone (chest down) positioning, used as an early intervention
for patients with severe ARDS (SARDS), significantly decreased mortality by
50% after 28 days and 42% after 90 days (p<0.001). A significant reduction in
ventilator-free days was also observed over similar periods for patients in
the prone group.

The June 2013 publication described results of a multicenter, prospective,
randomized, controlled trial involving 466 patients. Mortality was
significantly lower in the group of ventilated SARDS patients who were placed
in the prone position for at least 16 hours per day, compared to patients left
in the supine (chest up) position. The incidence of complications did not
differ significantly between the groups, except for the incidence of cardiac
arrests, which was higher in the supine group.

Angel Delgado, PhD, Director of Clinical Development & Clinical Sciences for
ArjoHuntleigh, said: “Previous trials involving ARDS patients and prone
positioning during mechanical ventilation have demonstrated a beneficial
effect and a trend toward improved mortality but none have reached statistical
significance. It is very encouraging to see in this study that early
application of prone positioning on SARDS patients has significant mortality

ArjoHuntleigh, a Getinge Group company, produces products that support prone
therapy, such as RotoProne Therapy System, TriaDyne Proventa Therapy System
and the Nimbus Professional System. Such products are designed to help reduce
the physical burden of repositioning patients according to prone positioning
protocols and to help prevent complications such as pressure ulcers. As with
all medical equipment, users should refer to the Indications for Use and such
equipment should only be prescribed by suitably qualified medical staff.

About ArjoHuntleigh

ArjoHuntleigh, a member of the Getinge Group, is a leading global provider of
equipment and systems that contribute to quality enhancement and cost
efficiency within healthcare and life sciences. Equipment, service and
technologies are supplied under the brands ArjoHuntleigh for patient handling
and hygiene, disinfection, DVT prevention, medical beds, therapeutic surfaces
and diagnostics, GETINGE for infection control and prevention within
healthcare and life science and MAQUET for surgical work places,
cardiopulmonary and critical care. ArjoHuntleigh offers a broad range of
integrated solutions for the care of people with reduced mobility and related
conditions, with the aim to enhance the quality of care in elderly care
facilities, hospitals and other healthcare environments. More information
about ArjoHuntleigh can be found at


For clinical questions, please contact:
Dr. Angel Delgado, PhD., Director Global Clinical Development & Clinical
For business-related questions, please contact:
Alex Myers, President & CEO
Tel: +46 767 612585
Press spacebar to pause and continue. Press esc to stop.